Top Industry News

AbbVie has announced a $1.4-billion investment to build a new 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The investment is part of the company’s $100-billion, 10-year capital investment plan in the US, which includes R&D and manufacturing,…

Merck & Co. and Google Cloud have announced a multi-year partnership, worth up to $1 billion, to enhance Merck’s digital backbone in artificial intelligence (AI) by deploying an agentic AI platform across Merck’s research & development (R&D), manufacturing, commercial, and corporate functions.  The partnership includes…

Eli Lilly and Company has agreed to acquire Kelonia Therapeutics, a Boston-based clinical-stage bio/pharmaceutical company specializing in in vivo gene delivery, in a $7-billion deal ($3.25 billion upfront and $3.75 billion in milestone payments).  Kelonia has developed a proprietary in vivo gene-placement system, iGPS, which uses specially engineered…

Servier, a French bio/pharmaceutical company, has completed its $2.5-billion acquisition of Day One Biopharmaceuticals, a Brisbane, California-based bio/pharmaceutical developing oncology drugs. The companies had announced the acquisition last month (March 2026).   Day One’s portfolio…

The latest from CDMOs, CMOs, and suppliers featuring Evonik, Alcami, Tjoapack, Piramal Pharma, Ajinomoto Bio-Pharma Service, and Avantor.   Chemical/Chemical API Manufacturing * Piramal Pharma, Ajinomoto Bio-Pharma Services Form Strategic Collaboration in ADCsBiologics…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring UCB, Amneal, Biogen and Asahi Kasei. Highlights below.   For the latest news roundup on small and Emerging Pharma…

The latest from small and Emerging Pharma companies featuring Ray Therapeutics and Tortugas Neuroscience.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * Ray Therapeutics Raises $125…

Regeneron Pharmaceuticals, a Tarrytown, New York-based bio/pharmaceutical company, and Telix Pharmaceuticals, a Melbourne, Australia-based clinical-stage bio/pharmaceutical company, have entered a collaboration to jointly develop and commercialize radiopharmaceutical therapies, in a deal worth up to $2.1 billion ($40…

In a move to focus on its core prescription drug business, Daiichi Sankyo has agreed to divest its consumer healthcare business, Daiichi Sankyo Healthcare Co. (DSHC), to Suntry Holdings, an Osaka Japan-based food and…

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for treating RAS-addicted cancers, is seeking to raise $2 billion through a follow-on stock offering of 10.56 million shares priced at $142…